Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy

•Prevalence of moderate-to-severe ocular complications of anti PD-(L)1 is 0.4% and incidence is 0.7 per 1000 patient-months. •Main clinical patterns include intraocular inflammation, ocular surface disease, and orbital myopathy. •Ocular complications usually start early after the onset of treatments but can be delayed. •Orbital myopathies may be associated with life-threatening myocarditis. Purpose Immune checkpoint inhibitors (ICI) targeting...